Gabapentin - A New Anticonvulsant
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Gabapentin - A New Anticonvulsant
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 921
Article Code: 921b
Date: April 29, 1994
Volume: 36
Pages: 39-40
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 921
Article Code: 921b
Date: April 29, 1994
Volume: 36
Pages: 39-40
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)